NCT00390845

P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain

A Double-blind Placebo-controlled Study of the Efficacy and Safety of the P38 Map Kinase Inhibitor SB681323 in Patients With Neuropathic Pain Following Nerve Trauma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This will be a double-blind, placebo controlled cross-over study. After enrolment and initial assessments, subjects will receive oral SB681323 or matching placebo for 14 days. SB681323 will be administered twice daily at a total daily dose of 7.5mg. Sufficient numbers of patients will be recruited to obtain 40 evaluable patients

Conditions

• Pain, Neuropathic

Interventions

Type	Name	Description
DRUG	SB681323	15 milligrams (mg)/day
DRUG	Placebo

Timeline

• Start date: 2006-08-30
• Primary completion: 2008-08-11
• Completion: 2008-08-11
• First posted: 2006-10-20
• Last updated: 2017-08-22

Locations

13 sites across 4 countries: Australia, Germany, Russia, United Kingdom